Your browser doesn't support javascript.
loading
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz, Orly; McIntyre, Roger S; Rodrigues, Nelson B; Kaster, Tyler S; Cha, Danielle S; Brietzke, Elisa; Gill, Hartej; Nasri, Flora; Lin, Kangguang; Subramaniapillai, Mehala; Kratiuk, Kevin; Teopiz, Kayla; Lui, Leanna M W; Lee, Yena; Ho, Roger; Shekotikhina, Margarita; Mansur, Rodrigo B; Rosenblat, Joshua D.
Affiliation
  • Lipsitz O; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • McIntyre RS; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Brain and Cognition Discovery Foundation, Canada; Department of Psychiatry, University of Toronto,
  • Rodrigues NB; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Kaster TS; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Cha DS; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Brietzke E; Queen's University School of Medicine, Kingston, ON, Canada; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.
  • Gill H; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Nasri F; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada.
  • Lin K; Department of Affective Disorder, the Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital, Guangzhou Medical University, Guangzhou, China; Laboratory of Emotion and Cognition, the Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital, Gua
  • Subramaniapillai M; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Kratiuk K; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Teopiz K; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Lui LMW; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada.
  • Lee Y; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Ho R; Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Shekotikhina M; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
  • Mansur RB; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Rosenblat JD; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Brain and Cognition Discovery Foundation, Canada; Department of Psychiatry, University of Toronto,
Prog Neuropsychopharmacol Biol Psychiatry ; 105: 110126, 2021 03 08.
Article in En | MEDLINE | ID: mdl-33031861
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depressive Disorder, Treatment-Resistant / Ketamine / Antidepressive Agents Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Prog Neuropsychopharmacol Biol Psychiatry Year: 2021 Document type: Article Affiliation country: Canada Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depressive Disorder, Treatment-Resistant / Ketamine / Antidepressive Agents Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Prog Neuropsychopharmacol Biol Psychiatry Year: 2021 Document type: Article Affiliation country: Canada Country of publication: United kingdom